Navigation Links
Rules-Based Medicine Introduces CardiovascularMAP(TM) Multiplex Biomarker Panel to Aid CVD Drug Development
Date:10/28/2009

AUSTIN, Texas, Oct. 28 /PRNewswire/ -- Rules-Based Medicine (RBM), a leading multiplexed biomarker testing laboratory, today announced the launch of CardiovascularMAP, a research tool designed specifically to advance drug development aimed at the treatment of cardiovascular disease (CVD.) Designed in collaboration with leading pharmaceutical and biotechnology research groups, the 50-biomarker panel combines biomarkers most commonly associated with CVD progression with additional markers to identify new patterns of disease, resulting in a potentially powerful new tool for researchers.

"RBM is providing access to the most comprehensive array of cardiovascular biomarkers ever assembled in one panel," said George P. Rodgers, M.D., F.A.C.C., past chairman of the American College of Cardiology Board of Governors. "Accurate measurement of these biomarkers clearly has the potential to accelerate CVD research programs."

CardiovascularMAP is based on RBM's proprietary Multi-Analyte Profiling (MAP) platform, which quantifies key blood-based biomarkers representing dozens of important biological pathways. The multiplexing process allows for an optimized panel intended to heighten efficiency while providing high levels of accuracy and precision.

"As researchers gain appreciation for the critical role inflammation plays in cardiovascular and other diseases, it is important to combine known CVD biomarkers with those that report on multiple associated pathways," said Craig Benson, RBM president and chief executive officer. "Our multiplexed panel for cardiovascular disease provides researchers with a cost-effective tool to measure established CVD biomarkers while also identifying new biomarker patterns for further exploration."

Cardiovascular disease is the leading cause of morbidity and mortality in the United States. CVD follows a progression that begins with the evolution of risk factors that contribute to the development of subclinical atherosclerosis. Subclinical disease typically goes undetected until the onset of overt CVD marked by symptoms such as chest pain, shortness of breath, dizziness and fainting. Patients with overt CVD have a poor prognosis with increased risk of recurrent events, morbidity, and mortality. Systemic inflammation and abnormal lipoprotein metabolism have been documented as important contributors to the progression of atherosclerotic disease and plaque instability.

Many of the events in the progression of CVD can be monitored using biomarkers found in blood. For a complete list of the CardiovascularMAP analytes and details regarding sample submission, please refer to www.rulesbasedmedicine.com.

About Rules-Based Medicine, Inc.

Rules-Based Medicine (RBM) is a CLIA-certified biomarker testing laboratory that solves complex therapeutic development, diagnostic and treatment challenges with innovative products and services. The Company's proprietary Multi-Analyte Profiling (MAP) platform makes the drug discovery and development process more efficient and effective by providing pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins from small sample volumes. Building on the MAP platform, RBM has developed a host of solutions including: a self-contained whole-blood culture system that brings reproducibility and simplicity to ex vivo immune response measurement; novel and companion diagnostic tests for complex diseases and therapies; therapeutic-specific MAPs custom designed for late-stage clinical development; and new assays for the early detection of renal damage. Additional information on RBM is available via the worldwide web at www.rulesbasedmedicine.com.

CardiovascularMAP(TM) is a trademark of Rules-Based Medicine, Inc.

SOURCE Rules-Based Medicine, Inc.


'/>"/>
SOURCE Rules-Based Medicine, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Mark Popovsky Receives Prominent Award for Leadership in Transfusion Medicine
2. High Blood Pressure Medicines Show Promise For Treating Heart Disease
3. Emergency Medicine Physicians Announces Six New Contracts With North Carolina Hospitals
4. Personalized Medicine Killer Apps Will Transform Care Model
5. Personalized Medicine Expert: Dont Fix It, Predict It
6. Safe Drug Drop Off - Sheriff Baca, LA County Communities, and Narconon Join Together to Get Drugs Out of the Medicine Cabinet
7. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
8. Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
9. Hard To Treat Diseases (HTDS.PK) Stem Cells and Regenerative Medicine
10. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
11. Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... MOUNTAIN VIEW, Calif. , Dec. 8, 2016 ... it intends to offer newly issued shares of common stock, ... "Shares") pursuant to an underwritten public offering.  The final terms ... at the time of pricing, and there can be no ... completed. IRIDEX expects to use the net proceeds ...
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)...  The global biosurgery market is expected to grow ... of 2016 to 2021. The market is poised to ... billion in 2016. The market is primarily driven by ... injuries and spinal problems, increasing clearance of biosurgery products ... loss management. In this report, the biosurgery ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa Wound ... Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the ... hospitals and facilities have earned this distinction. This is the second time the ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the ... series, and attorneys from the firm’s global Life Sciences & Medical Technology Group have ...
Breaking Medicine News(10 mins):